Tag: CHRS, Analyst Rating

Coherus BioSciences, Inc. receives a $296,000 investment from the Louisiana State Employees Retirement System (NASDAQ:CHRS)

by Roberto Liccardo

January 14, 2023

The most recent filing that the Louisiana State Employees Retirement System made with the Securities and Exchange Commission (SEC) revealed ...

The stock price of Coherus BioSciences (NASDAQ:CHRS) has dropped 7.9% as a result of an analyst downgrade.

by Roberto Liccardo

November 18, 2022

Following Mizuho's announcement that they would be lowering their price objective for Coherus BioSciences, Inc. (NASDAQ: CHRS) from $28.00 to ...

JPMorgan Chase & Co. reduced Coherus BioSciences (NASDAQ:CHRS) PT to $11.00.

by Roberto Liccardo

November 15, 2022

Barclays increased the price objective it had set for American Tower (NYSE: AMT) from $232.00 to $247.00, according to information ...

DISCLAIMER

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

Follow us on Social Media
Facebook – YouTube – Twitter

Write for us
Finance – Business